Skip to main content

Table 6 Group comparison (mean ± SD) in secondary outcome measures between patients on lovastatin vs. placebo

From: Controlled trial of lovastatin combined with an open-label treatment of a parent-implemented language intervention in youth with fragile X syndrome

Outcome

Lovastatin+PILI

Placebo+PILI

Baseline

Post

Baseline

Post

Receptive vocab growth score

134.75 ± 31.76

136.92 ± 33.87

137.44 ± 22.71

136.44 ± 19.79

Expressive vocab growth score

143.5 ± 22.12

142.67 ± 24.53

141.44 ± 14.45

142.75 ± 12.91

Expressive grammar raw score

10.18 ± 11.36

11 ± 12.66

8.33 ± 6.41

9.93 ± 7.59

Receptive grammar raw score

22.18 ± 18.91

22.17 ± 20.23

21.4 ± 9.26

20.2 ± 11.98

Parent strategy: recasts

3.28 ± 2.67

29.67 ± 13.34

5.48 ± 5.07

24.79 ± 12.57

Parent strategy: WH-questions

9.56 ± 9.06

40.36 ± 20.69

13.19 ± 8.57

33.25 ± 17.73

Parent strategy: fill-in-the-blank prompts

2.06 ± 2.74

19.56 ± 11.96

3.21 ± 6.96

16.5 ± 14.24

ABC-C – total score

44.5 ± 28.43

40.5 ± 31.83

55.5 ± 30.18

44.06 ± 25.36

RBS-R – total score

27.75 ± 17.43

28.67 ± 23.9

32.19 ± 18.84

26.19 ± 20.14

Clinical Global Impression (CGI)

4.581 ± 0.67

2.422 ± 0.67

4.501 ± 0.63

2.382 ± 0.72

VAS: spoken language impairment

4.06 ± 2.43

5.66 ± 1.99

1.94 ± 1.41

4.18 ± 1.53

VAS: social impairment

3.73 ± 1.74

5.18 ± 1.70

2.55 ± 1.36

3.99 ± 2.06

  1. 1CGI-severity ratings collected at baseline visit
  2. 2CGI-improvement ratings collected at post-treatment visit